We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Product News   Apr 15, 2019

 
QIAGEN Launches First FDA-approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Image credit: QIAGEN

 
 
FURTHER INFORMATION
 
 
 

Related Product News


Adapter Enables Parallel Chemical Reactions at Over 400°C

Product News

Asynt announces the DrySyn Multi-M high temperature adapter - a unique product that enables scientists to undertake parallel reactions that require solution temperatures of over 400°C.

READ MORE

South Africa Invests in Flow Chemistry

Product News

Uniqsis reports on two major orders for its FlowSyn™ flow chemistry systems from organisations involved with the South African Pharmaceutical Industry.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cancer Research Cell Science Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE